Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shambavi Richard

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Seminars in Hematology|February 28, 2025
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapiesLarysa Sanchez, Shambavi Richard
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 3, 2022
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyShambavi Richard, Sundar Jagannath
Current Hematology Reports|August 7, 2003
Stem cell transplantation and hematopoietic growth factorsShambavi Richard, Michael W Schuster
Future Oncology (London, England)|June 9, 2020
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myelomaShambavi Richard, Joshua Richter, Sundar Jagannath
Therapeutic Advances in Hematology|June 23, 2020
Selinexor in relapsed/refractory multiple myelomaJoshua Richter, Deepu Madduri, Shambavi Richard, et al.
Therapeutic Advances in Hematology|April 2, 2021
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapiesLarysa Sanchez, Alexandra Dardac, Deepu Madduri, et al.
Expert Review of Hematology|September 21, 2021
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weeklyXavier Leleu, Ajai Chari, Shambavi Richard, et al.
Expert Review of Hematology|December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myelomaShambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Clinical Nephrology|November 21, 2012
Reversible left ventricular dysfunction and acute kidney injury in a patient with nonamyloid light chain deposition diseaseNand K Wadhwa, Amit Kamra, Hal A Skopicki, et al.
British Journal of Haematology|March 29, 2002
Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesisShambavi Richard, Luis Isola, Eileen Scigliano, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Seminars in Hematology|February 28, 2025
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapiesLarysa Sanchez, Shambavi Richard
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 3, 2022
Targeting Nuclear Export Proteins in Multiple Myeloma TherapyShambavi Richard, Sundar Jagannath
Current Hematology Reports|August 7, 2003
Stem cell transplantation and hematopoietic growth factorsShambavi Richard, Michael W Schuster
Future Oncology (London, England)|June 9, 2020
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myelomaShambavi Richard, Joshua Richter, Sundar Jagannath
Therapeutic Advances in Hematology|June 23, 2020
Selinexor in relapsed/refractory multiple myelomaJoshua Richter, Deepu Madduri, Shambavi Richard, et al.
Therapeutic Advances in Hematology|April 2, 2021
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapiesLarysa Sanchez, Alexandra Dardac, Deepu Madduri, et al.
Expert Review of Hematology|September 21, 2021
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weeklyXavier Leleu, Ajai Chari, Shambavi Richard, et al.
Expert Review of Hematology|December 17, 2020
A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myelomaShambavi Richard, Sundar Jagannath, Hearn Jay Cho, et al.
Clinical Nephrology|November 21, 2012
Reversible left ventricular dysfunction and acute kidney injury in a patient with nonamyloid light chain deposition diseaseNand K Wadhwa, Amit Kamra, Hal A Skopicki, et al.
British Journal of Haematology|March 29, 2002
Syngeneic stem cell transplant for spent-phase polycythaemia vera: eradication of myelofibrosis and restoration of normal haematopoiesisShambavi Richard, Luis Isola, Eileen Scigliano, et al.
Pageof 6